- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00876447
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
April 18, 2019 updated by: Allergan
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
This is a follow-up study to two Allergan sponsored studies (NCT00311376 and NCT00461292).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Botulinum toxin Type A 300U has been discontinued from the study.
Patients remaining in the arm containing botulinum toxin Type A 300U will receive botulinum toxin Type A 200U moving forward.
Also, the masking of the study is now open-label.
Study Type
Interventional
Enrollment (Actual)
397
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Randwick, Australia
-
-
-
-
-
Innsbruck, Austria
-
-
-
-
-
Ghent, Belgium
-
-
-
-
-
Rio de Janeiro, Brazil
-
-
-
-
British Columbia
-
Victoria, British Columbia, Canada
-
-
-
-
-
Ostrava, Czechia
-
-
-
-
-
Salouel, France
-
-
-
-
-
Kiel, Germany
-
-
-
-
-
Florence, Italy
-
-
-
-
-
Amsterdam, Netherlands
-
-
-
-
-
Epsom, New Zealand
-
-
-
-
-
Poznan, Poland
-
-
-
-
-
Porto, Portugal
-
-
-
-
-
Moscow, Russian Federation
-
-
-
-
-
Singapore, Singapore
-
-
-
-
-
Presov, Slovakia
-
-
-
-
-
Pretoria, South Africa
-
-
-
-
-
Tenerife, Spain
-
-
-
-
-
Hualien, Taiwan
-
-
-
-
-
Kiev, Ukraine
-
-
-
-
-
London, United Kingdom
-
-
-
-
Connecticut
-
Middlebury, Connecticut, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patient has participated in study 191622-515 or 191622-516 and the following criteria fulfilled:
- Patient completed at least 52 weeks in the preceding study.
- No longer than 6 months has elapsed since completion of the preceding study
- Patient has not received any prohibited medications during any intervening period between the preceding study and this long-term study.
Exclusion Criteria:
- History or evidence of pelvic or urologic abnormality.
- Previous or current diagnosis of bladder or prostate cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Botulinum Toxin Type A 300U
Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
|
Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
Other Names:
|
Experimental: Botulinum Toxin Type A 200U
Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
|
Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes
Time Frame: Study Baseline, Week 6 Treatment Cycle 1
|
Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516).
The number of incontinence episodes are averaged daily during this period.
The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516.
A negative number change from baseline indicates a reduction in incontinence episodes (improvement).
|
Study Baseline, Week 6 Treatment Cycle 1
|
Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes
Time Frame: Study Baseline, Week 6 Treatment Cycle 2
|
Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516).
The number of incontinence episodes are averaged daily during this period.
The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516.
A negative number change from baseline indicates a reduction in incontinence episodes (improvement).
|
Study Baseline, Week 6 Treatment Cycle 2
|
Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes
Time Frame: Study Baseline, Week 6 Treatment Cycle 3
|
Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516).
The number of incontinence episodes are averaged daily during this period.
The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516.
A negative number change from baseline indicates a reduction in incontinence episodes (improvement).
|
Study Baseline, Week 6 Treatment Cycle 3
|
Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes
Time Frame: Study Baseline, Week 6 Treatment Cycle 4
|
Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516).
The number of incontinence episodes are averaged daily during this period.
The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516.
A negative number change from baseline indicates a reduction in incontinence episodes (improvement).
|
Study Baseline, Week 6 Treatment Cycle 4
|
Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes
Time Frame: Study Baseline, Week 6 Treatment Cycle 5
|
Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-094 (or 7 days prior to each visit in study 191622-515 or 191622-516).
The number of incontinence episodes are averaged daily during this period.
The initial study baseline is obtained from the patient bladder diary in the 7 consecutive days prior to the first treatment in either study 191622-515 or 191622-516.
A negative number change from baseline indicates a reduction in incontinence episodes (improvement).
|
Study Baseline, Week 6 Treatment Cycle 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score
Time Frame: Study Baseline, Week 6 Treatment Cycle 1
|
The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives.
Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL).
The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL).
The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improved QOL.
|
Study Baseline, Week 6 Treatment Cycle 1
|
Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score
Time Frame: Study Baseline, Week 6 Treatment Cycle 2
|
The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives.
Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL).
The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL).
The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improved QOL.
|
Study Baseline, Week 6 Treatment Cycle 2
|
Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score
Time Frame: Study Baseline, Week 6 Treatment Cycle 3
|
The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives.
Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL).
The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL).
The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improved QOL.
|
Study Baseline, Week 6 Treatment Cycle 3
|
Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score
Time Frame: Study Baseline, Week 6 Treatment Cycle 4
|
The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives.
Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL).
The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL).
The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improved QOL.
|
Study Baseline, Week 6 Treatment Cycle 4
|
Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score
Time Frame: Study Baseline, Week 6 Treatment Cycle 5
|
The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives.
Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL).
The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL).
The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improved QOL.
|
Study Baseline, Week 6 Treatment Cycle 5
|
Change From Study Baseline in Volume Per Void
Time Frame: Study Baseline, Week 6 Treatment Cycle 1
|
The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit.
The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improvement.
|
Study Baseline, Week 6 Treatment Cycle 1
|
Change From Study Baseline in Volume Per Void
Time Frame: Study Baseline, Week 6 Treatment Cycle 2
|
The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit.
The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improvement.
|
Study Baseline, Week 6 Treatment Cycle 2
|
Change From Study Baseline in Volume Per Void
Time Frame: Study Baseline, Week 6 Treatment Cycle 3
|
The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit.
The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improvement.
|
Study Baseline, Week 6 Treatment Cycle 3
|
Change From Study Baseline in Volume Per Void
Time Frame: Study Baseline, Week 6 Treatment Cycle 4
|
The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit.
The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improvement.
|
Study Baseline, Week 6 Treatment Cycle 4
|
Change From Study Baseline in Volume Per Void
Time Frame: Study Baseline, Week 6 Treatment Cycle 5
|
The total volume voided (voluntary or by catheterization) is recorded by the patient over a 24-hour period preceding the study visit.
The average volume per voiding episode is derived by dividing the total volume collected in a 24-hour period by the total number of urinary episodes with volume recorded in the same 24-hour period.
The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-515 or 191622-516.
Positive number changes from baseline indicate improvement.
|
Study Baseline, Week 6 Treatment Cycle 5
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2009
Primary Completion (Actual)
June 12, 2013
Study Completion (Actual)
September 4, 2013
Study Registration Dates
First Submitted
April 1, 2009
First Submitted That Met QC Criteria
April 3, 2009
First Posted (Estimate)
April 6, 2009
Study Record Updates
Last Update Posted (Actual)
May 1, 2019
Last Update Submitted That Met QC Criteria
April 18, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Urinary Bladder, Overactive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- 191622-094
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on Botulinum Toxin Type A 300U
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
Brazilan Center for Studies in DermatologyCompletedWrinkles in Frontal AreaBrazil
-
HugelCompletedBenign Masseteric HypertrophyKorea, Republic of
-
Buddhist Tzu Chi General HospitalCompletedSpinal Cord InjuriesTaiwan
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
Medy-ToxCompletedCervical Dystonia